Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Multicenter, Open-Label, Dose-Escalation and Extension Study of GQ1010(an Anti-Trop2 ADC) in Subjects With Advanced Solid Tumors

NCT06464055 is registered in ClinicalTrials.gov with GeneQuantum Healthcare (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT06464055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06464055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Multicenter, Open-Label, Dose-Escalation and Extension Study of GQ1010(an Anti-Trop2 ADC) in Subjects With Advanced Solid Tumors
Lead sponsor
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 23, 2024
Completion date
December 31, 2028
Enrollment
260 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumors